Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Ipilimumab 22Fluorouracil 22Azacitidine 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × troxacitabine × Clear all
NCT00104468 2008-01-17

Study of Troxatylâ„¢ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)

SGX Pharmaceuticals, Inc.

Phase 1/2 Terminated
50 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00104286 2006-11-03

Study of Troxatylâ„¢ Administered by Continuous Infusion to Subjects With Solid Tumors

SGX Pharmaceuticals, Inc.

Phase 1/2 Terminated
50 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡